Washington, D.C. (June 9, 2026) – In response to the House of Representatives’ Committee on Appropriations’ release of its FY2027 Labor, Health and Human Services, Education, and Related Agencies appropriations bill, UsAgainstAlzheimer’s Acting Chief Operating Officer Catherine Patterson issued the following statement:  

“Alzheimer’s disease remains one of the greatest health challenges facing our nation, affecting millions of Americans and the families who care for them. As the science continues to show the potential of risk reduction for Alzheimer’s disease, we appreciate that the House Appropriations Committee maintained funding for the Centers for Disease Control and Prevention’s Alzheimer’s Disease Program (ADP).

“We appreciate Chairman Aderholt and the Committee’s $100 million increase for the National Institutes of Health (NIH), including an additional $25 million for Alzheimer’s disease research.   NIH – especially the National Institute on Aging – remains the driving force behind efforts to better understand, prevent, treat, and ultimately cure Alzheimer’s. We are hopeful that as Congress continues its FY27 appropriations process, further increases for Alzheimer’s research can be included. 

“UsAgainstAlzheimer’s is especially pleased to see the bipartisan, bicameral language capping the amount of multi-year funding from fiscal year 2026’s final bill included in the manager’s amendment. This will maximize the number of opportunities for breakthroughs for new treatments for this dreaded disease. 

“We particularly appreciate the Committee’s inclusion of report language recognizing the disproportionate impact of Alzheimer’s disease on women and the need for greater research into sex-based differences in risk and treatment outcomes. Women account for nearly two-thirds of Americans living with Alzheimer’s, yet significant gaps remain in our understanding of the biological and social factors that shape their brain health. This focus aligns closely with UsAgainstAlzheimer’s Advancing Women’s Brain Health initiative, which is working to address gaps in research, public health, and policy and advance more precise approaches to risk reduction, diagnosis, and treatment. 

“Progress against Alzheimer’s requires both groundbreaking research and strong public health programs. We appreciate the committee's continued commitment to these priorities in the FY2027 Labor-HHS bill and urge Congress to continue building on that commitment throughout the FY2027 appropriations process so that momentum is not lost and families can continue to benefit from advances in risk reduction, treatment, care, and, ultimately, a cure.”

###

About UsAgainstAlzheimer’s  

UsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations—the people who put the “Us” in UsAgainstAlzheimer’s.

Contact: Chantez Bailey, [email protected]